Bernhard Heinrich

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

G. Dresemann, Michael Weller, Mark Rosenthal et al. · Journal of Neuro-Oncology · 2009 · 156 citations

Medicine, Oncology, Pharmacotherapy +11

Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer

Hans‐Joachim Stemmler, S. Kahlert, Wolfgang Siekiera et al. · The Breast · 2005 · 154 citations

Medicine, Oncology, Metastasis +13

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

Gϋnter von Minckwitz, Gϋnter von Minckwitz, Sibylle Loibl et al. · Annals of Oncology · 2014 · 140 citations

Medicine, Oncology, Pharmacology +15